{"organizations": [], "uuid": "ef8e7eeb51ef8bb515f98ffaa5894c851fc28624", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/21/business-wire-novabay-pharmaceuticals-to-hold-2017-fourth-quarter-and-full-year-conference-call-on-march-20-2018.html", "country": "US", "domain_rank": 767, "title": "NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T14:50:00.000+02:00", "replies_count": 0, "uuid": "ef8e7eeb51ef8bb515f98ffaa5894c851fc28624"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/21/business-wire-novabay-pharmaceuticals-to-hold-2017-fourth-quarter-and-full-year-conference-call-on-march-20-2018.html", "ord_in_thread": 0, "title": "NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "emeryville", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nby", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "novabay pharmaceuticals", "sentiment": "negative"}, {"name": "novabay ® pharmaceuticals, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 fourth quarter and full year financial results after market close on Tuesday, March 20. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.\nDATE: Tuesday, March 20 TIME: 4:30 p.m. ET / 1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S. 702-495-1913 from outside the U.S. Enter conference identification number 68570527 The live call also will be available at http://novabay.com/investors/events . A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Pacific time April 20, 2018, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 2764067. The call will also be archived at http://novabay.com/investors/events .\nAbout NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.\nSocialize and Stay informed on NovaBay’s progress:\nLike us on Facebook\nFollow us on Twitter\nConnect with NovaBay on LinkedIn\nJoin us on Google+\nVisit NovaBay’s Website\nNovaBay Contacts\nFor NovaBay Avenova purchasing information:\nPlease Call us toll free: 1-800-890-0329 or email sales@avenova.com .\nwww.Avenova.com\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180221005416/en/\nNovaBay Pharmaceuticals, Inc.\nJack McGovern\nChief Financial Officer\n510-899-8800\njmcgovern@novabay.com\nor\nInvestor Contact\nLHA Investor Relations\nJody Cain\n310-691-7100\njcain@lhai.com\nSource: NovaBay Pharmaceuticals, Inc.", "external_links": ["http://novabay.com/investors/events", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnovabay.com%2Finvestors%2Fevents&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=http%3A%2F%2Fnovabay.com%2Finvestors%2Fevents&index=2&md5=03081297a027d43eab40265db7ac034f", "http://www.businesswire.com/news/home/20180221005416/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnovabay.com%2F&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=NovaBay%C2%AE+Pharmaceuticals%2C+Inc.&index=1&md5=b09936e90e44e670b158e4e91428fb27", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnovabay.com%2F&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=Website&index=8&md5=024083eff274427f1eb140ecde0bd4f7", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ilidcleanser.com%2F&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=www.Avenova.com&index=9&md5=b430fc251b86bc8bd0ce347e9f754e0d", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fplus.google.com%2Fu%2F0%2Fb%2F117083101479525995769%2F117083101479525995769%2Fposts&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=Google%2B&index=7&md5=5e4f669656b16b9cf4843f64dca6de64", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnovabay.com%2Finvestors%2Fevents&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=http%3A%2F%2Fnovabay.com%2Finvestors%2Fevents&index=3&md5=635b4635f041b1984ebc4e62cdc931b2", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnovabay-pharmaceuticals&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=LinkedIn&index=6&md5=8c90b084c859c5d0e17789a31e9f1558", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FNovaBay&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=Twitter&index=5&md5=c657f97f602804e106eb3fe0ca29b24e", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fnovabaypharma&esheet=51761800&newsitemid=20180221005416&lan=en-US&anchor=Facebook&index=4&md5=0a80e770486cc05b385438723d10a260"], "published": "2018-02-21T14:50:00.000+02:00", "crawled": "2018-02-21T16:51:37.001+02:00", "highlightTitle": ""}